Aripiprazole (ABILIFY MAINTENA®): A Review of Its Use as Maintenance Treatment for Adult Patients with Schizophrenia
- 27 June 2014
- journal article
- review article
- Published by Springer Science and Business Media LLC in Drugs
- Vol. 74 (10), 1097-1110
- https://doi.org/10.1007/s40265-014-0231-7
Abstract
Aripiprazole (ABILIFY®) is an atypical antipsychotic drug that is proposed to act via partial agonism of dopamine D2 receptors. Trials with oral aripiprazole have shown that, compared with some other atypical antipsychotics, aripiprazole is associated with fewer metabolic disturbances and has a favourable cardiovascular tolerability profile. Recently, an intramuscular long-acting injectable (LAI) depot formulation of aripiprazole (ABILIFY MAINTENA®) (aripiprazole LAI) has been approved for use as a treatment for schizophrenia in adults. The efficacy of aripiprazole LAI as a maintenance treatment for schizophrenia has been demonstrated in randomized clinical trials. In the trials, aripiprazole LAI was more effective than placebo, and noninferior to oral aripiprazole, in delaying relapse and in reducing relapse rates in schizophrenia. Aripiprazole LAI was generally well tolerated, with a tolerability profile consistent with that of oral aripiprazole. Thus, aripiprazole LAI is a valuable new treatment option for adult patients with schizophrenia. It may be of particular use for patients stable on oral aripiprazole who would prefer, or are likely to benefit from, a long-acting formulation.Keywords
This publication has 48 references indexed in Scilit:
- Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysisThe Lancet, 2013
- Metabolic Syndrome in SchizophreniaIndian Journal of Psychological Medicine, 2013
- Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophreniaJournal of Medical Economics, 2013
- Efficacy and safety of second-generation long-acting injections in schizophreniaInternational Clinical Psychopharmacology, 2013
- AripiprazoleDrugs, 2012
- Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysisSchizophrenia Research, 2010
- Second-Generation Antipsychotic Drugs and Extrapyramidal Side Effects: A Systematic Review and Meta-analysis of Head-to-Head ComparisonsSchizophrenia Bulletin, 2010
- The cost of relapse and the predictors of relapse in the treatment of schizophreniaBMC Psychiatry, 2010
- The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary StatementsSchizophrenia Bulletin, 2009
- Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study exampleCost Effectiveness and Resource Allocation, 2009